Toll‐like Receptor 9 Signaling Is Augmented in Systemic Sclerosis and Elicits Transforming Growth Factor β–Dependent Fibroblast Activation
Arthritis & Rheumatology2016Vol. 68(8), pp. 1989–2002
Citations Over TimeTop 10% of 2016 papers
Feng Fang, Roberta Gonçalves Marangoni, Xingchun Zhou, Yang Yang, Boping Ye, Anna Shangguang, Wenjie Qin, Wenxia Wang, Swati Bhattacharyya, Jun Wei, Warren G. Tourtellotte, John Varga
Abstract
In isolated fibroblasts, TLR9 elicits fibrotic responses mediated via endogenous TGFβ. In patients with SSc, mtDNA and other damage-associated TLR9 ligands in the skin might trigger localized activation of TLR9 signaling, TGFβ production, and consequent fibroblast activation. Disrupting this fibrotic process with inhibitors targeting TLR9 or its downstream signaling pathways might therefore represent a novel approach to SSc therapy.
Related Papers
- → Toll-like receptor 9 mediates CpG-DNA signaling(2002)192 cited
- → Baseless Assumptions: Activation of TLR9 by DNA(2008)6 cited
- → P151 Ligand recognition profiles of TLR9 from different species(2012)
- Recent Advances in Toll-like Receptor 9 and Its Ligands(2010)
- Toll-like receptor 9 and Systemic Lupus Erythromatosus: novel insights(2009)